| ASSET | QUARTER | % RETURN |
|---|---|---|
EXACT Sciences (EXAS) | Q1 2017 | 73.55% |
Summit Therapeutics (SMMT) | Q1 2017 | 57.66% |
Celsius (CELH) | Q1 2017 | 54.76% |
NRG Energy (NRG) | Q1 2017 | 52.06% |
Vertex Pharmaceuticals (VRTX) | Q1 2017 | 46.92% |
YPF Sociedad Anonima (YPF) | Q1 2017 | 44.52% |
Exelixis (EXEL) | Q1 2017 | 43.13% |
DexCom (DXCM) | Q1 2017 | 42.4% |
Howmet Aerospace (HWM) | Q1 2017 | 40.93% |
Ascendis Pharma A-S (ASND) | Q1 2017 | 40.21% |
STMicroelectronics NV ADR (STM) | Q1 2017 | 39.11% |
Arista Networks (ANET) | Q1 2017 | 35.61% |
Lumentum (LITE) | Q1 2017 | 35.41% |
Alnylam Pharmaceuticals (ALNY) | Q1 2017 | 34.34% |
QXO (QXO) | Q1 2017 | 33.9% |
MercadoLibre (MELI) | Q1 2017 | 33.17% |
Builders FirstSource (BLDR) | Q1 2017 | 32.8% |
Trade Desk (TTD) | Q1 2017 | 32.8% |
Incyte (INCY) | Q1 2017 | 32.16% |
Illumina (ILMN) | Q1 2017 | 32.11% |
Wynn Resorts (WYNN) | Q1 2017 | 32.1% |
Jazz Pharmaceuticals (JAZZ) | Q1 2017 | 31.94% |
Micron Technology (MU) | Q1 2017 | 30.95% |
Penumbra (PEN) | Q1 2017 | 30.8% |
IDEXX Laboratories (IDXX) | Q1 2017 | 30.7% |
Large-cap stocks are treated as having a market cap of $10B+.
